Oral Delivery of Nucleic Acid Drugs
Nucleic acid molecules have emerged as versatile tools with promising utility in a variety of biochemical, diagnostic, and therapeutic applications. A parenteral administration of a nucleic acid is inconvenient because of pain, fear, and risks being associated with this type of application. The intestinal epithelium is considered to be an attractive site for oral delivery of therapeutic genes.
The successful development of oral nucleic acid delivery systems is challenged by a variety of barriers encountered with the GI tract. The intestinal mucosa is both a physical and a biochemical barrier, separating the external environment from the internal milieu of the body.
Despite the enormous potential of gene therapy, safe and efficient delivery of nucleic acid into cells is still a dominant task in current biotechnological research. The majority of nucleic acid therapeutics are to a higher degree dependent on delivery systems for successful therapeutic intervention than conventional drugs.
Regarding safety concerns, non-viral gene delivery vehicles that have the required efficiency and safety for use in human gene therapy are being widely investigated as possible alternatives. Non-viral systems show a significantly lower safety risk and can be tailored to specific therapeutic needs.
KeywordsAntisense Oligonucleotide Oral Delivery Permeation Enhancer Methyl Phosphonates Sigmoid Colon Cancer
- Agrawal, S., X. Zhang, Z. Lu, H. Zhao, J. M. Tamburin, J. Yan, H. Cai, R. B. Diasio, I. Habus and Z. Jiang (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50(4): 571–6.PubMedCrossRefGoogle Scholar
- Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J. L. Villeval, C. C. Fraser, M. Cavazzana-Calvo and A. Fischer (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348(3): 255–6.PubMedCrossRefGoogle Scholar
- Raoof, A. A., P. Chiu, Z. Ramtoola, I. K. Cumming, C. Teng, S. P. Weinbach, G. E. Hardee, A. A. Levin and R. S. Geary (2004). Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci 93(6): 1431–9.PubMedCrossRefGoogle Scholar
- Raper, S. E., N. Chirmule, F. S. Lee, N. A. Wivel, A. Bagg, G. P. Gao, J. M. Wilson and M. L. Batshaw (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80(1–2): 148–58.PubMedCrossRefGoogle Scholar
- Sweetser, D. A., S. M. Hauft, P. C. Hoppe, E. H. Birkenmeier and J. I. Gordon (1988). Transgenic mice containing intestinal fatty acid-binding protein human growth-hormone fusion genes exhibit correct regional and cell-specific expression of the reporter gene in their small-intestine. Proc Natl Acad Sci USA 85(24): 9611–9615.PubMedCrossRefGoogle Scholar